Protocol summary

Study aim
Due to ongoing controversy regarding calcium gluconate use in cardiac surgery patients, further evaluation of its effects on postoperative outcomes may have important implications for patient management and clinical outcomes.
Design
Children will be randomly assigned to hypocalcemia and normal calcium groups receiving different doses of intravenous calcium gluconate to reach target serum calcium levels. The study is double-blind, and the drug is prepared similar to normal saline. Data will be analyzed using SPSS version 22.
Settings and conduct
This randomized clinical trial will be conducted at Shahid Modarres Hospital on pediatric patients after cardiac surgery. Patients will be assigned to hypocalcemia and normal calcium groups and will receive calcium gluconate. The study is double-blind, and the drug is prepared similarly to normal saline for blinding.
Participants/Inclusion and exclusion criteria
Inclusion Age ≤18 years Hospitalization for cardiac surgery Documented serum calcium level Exclusion Underlying metabolic or endocrine disorders Severe non-cardiac illness Refusal of patient/parent/legal guardian consent Serious adverse events during the study History of hypersensitivity to calcium gluconate
Intervention groups
Hospitalized pediatric patients after cardiac surgery will be enrolled following informed consent. Patients with hypocalcemia will receive standard calcium therapy, while those with normal calcium levels will receive continuous calcium gluconate infusion until a predefined upper target level. Clinical outcomes will be compared between the two groups.
Main outcome variables
ICU and hospital length of stay; mortality/overall outcome; serum calcium levels; mechanical ventilation; inotropic support; hemodynamic changes ; major complications.

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20260615069812N1
Registration date: 2026-10-05, 1405/07/13
Registration timing: registered_while_recruiting

Last update: 2026-10-05, 1405/07/13
Update count: 0
Registration date
2026-10-05, 1405/07/13
Registrant information
Name
maryam zeinali
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 2208 3101
Email address
maryamzeinali@sbmu.ac.ir
Recruitment status
recruiting
Funding source
Expected recruitment start date
2026-06-20, 1405/03/30
Expected recruitment end date
2027-03-20, 1405/12/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of the effect of Calcium Gluconate drip treatment in pediatrics with normal calcium level after cardiac surgery
Public title
Calcium Gluconate drip treatment in pediatrics with normal calcium level after cardiac surgery
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age ≤ 18 years Hospitalization for cardiac surgery-related disease Availability of documented serum calcium level measurements
Exclusion criteria:
Presence of underlying metabolic or endocrine disorders Severe non-cardiac medical illness Refusal of participation by the patient or parent/legal guardian Development of severe adverse events during the study History of hypersensitivity to calcium gluconate
Age
To 19 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Investigator
Sample size
Target sample size: 54
Randomization (investigator's opinion)
Randomized
Randomization description
Group 1 (Hypocalcemic Group): Patients with hypocalcemia will receive intravenous calcium gluconate infusion at a dose of 1 mg/kg/hour. The infusion will be continued until the serum calcium level reaches the normal range, defined as at least 8.5 mg/dL. Group 2 (Normocalcemic Group): Children with normal serum calcium levels will receive intravenous calcium gluconate infusion at a dose of 0.5 mg/kg/hour. The infusion will be continued until the serum calcium level reaches the upper normal limit of 10.5 mg/dL, after which the infusion will be discontinued.
Blinding (investigator's opinion)
Double blinded
Blinding description
This study will be conducted using a double-blind design, whereby neither the investigators nor the parents/legal guardians will be aware of the treatment allocation. To maintain blinding, calcium gluconate infusions and placebo (normal saline) infusions will be prepared and administered in an identical manner.
Placebo
Used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Shahid Beheshti University of Medical Sciences
Street address
Shahid Modarres Hospital, Yadegar-e-Emam Highway, Saadat Abad intersection, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1998734421
Approval date
2024-10-27, 1403/08/06
Ethics committee reference number
IR.SBMU.RETECH.REC.1403.438

Health conditions studied

1

Description of health condition studied
Children undergoing cardiac surgery
ICD-10 code
Q20
ICD-10 code description
Congenital malformations of cardiac chambers and connections

Primary outcomes

1

Description
Calcium level, duration of ICU and hospital stay, duration of intubation, and the degree of inotrope requirement
Timepoint
Serum calcium levels in children are measured at specific time points (before the start of treatment, during the course of treatment, and after completion of treatment).
Method of measurement
Medical record.

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Group 1 consists of patients with hypocalcemia who receive intravenous calcium gluconate treatment. The dose of calcium gluconate in this group is 1 mg/kg/hour administered as an intravenous drip until the serum calcium level reaches at least the normal range (≥ 8.5 mg/dL). In Group 2, children with normal serum calcium levels receive a calcium gluconate infusion at a dose of 0.5 mg/kg/hour. The infusion is continued until the serum calcium level reaches a higher target (> 10.5 mg/dL), after which the infusion is discontinued.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Shahid Modarres Hospital
Full name of responsible person
Kourosh Vahidshahi
Street address
Yadegar-e-Emam Highway, Saadatabad Junction, Shahid Modares Hospital, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1998734383
Phone
+98 21 2207 4087
Email
maryamzeinali@sbmu.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Kourosh Vahidshahi
Street address
Yadegar-e-Emam Highway, Saadatabad Junction, Shahid Modares Hospital, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1998734383
Phone
+98 21 2207 4088
Email
maryamzeinali@sbmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
maryam zeinali
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
pediatric cardiology
Street address
saadat abad , modarres hospital
City
Tehran
Province
Tehran
Postal code
1998734383
Phone
+98 21 2208 3095
Email
maryamzeinali@sbmu.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
maryam zeinali
Position
Assistant Professor
Latest degree
Subspecialist
Other areas of specialty/work
Cardiology
Street address
Saadat abad , Modarres hospial
City
Tehran
Province
Tehran
Postal code
1998734383
Phone
+98 21 2208 3095
Email
maryamzeinali@sbmu.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Maryam Zeinal
Position
Assistant Professor
Latest degree
Subspecialist
Other areas of specialty/work
Cardiology
Street address
Saadat abad, Modarres Hospital
City
Tehran
Province
Tehran
Postal code
1998734383
Phone
+98 21 2208 3095
Email
maryamzeinali@sbmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
The data and study-related documents will be shared only after all personal identifiers and confidential information have been removed. De-identified data may be made available to qualified researchers upon reasonable request and with approval from the principal investigator, solely for scientific and research purposes. Data sharing will be conducted through secure electronic transfer or by depositing the data in an appropriate research data repository, where applicable. The study protocol, data collection instruments, and other relevant study documents may also be shared upon request, provided that confidentiality and ethical requirements are fully maintained. All data sharing will be carried out in accordance with applicable research ethics guidelines and data protection regulations.
When the data will become available and for how long
Data will be available upon completion of data collection
To whom data/document is available
Principal Investigator, study team members, and qualified researchers upon reasonable request and approval
Under which criteria data/document could be used
For scientific and research purposes only, subject to confidentiality requirements and approval by the Principal Investigator.
From where data/document is obtainable
The Principal Investigator of the study ( email)
What processes are involved for a request to access data/document
Data/document access requests will be reviewed by the Principal Investigator. Access will be granted after approval of the request and confirmation of compliance with confidentiality and research ethics requirements.
Comments
Loading...